Brand Name
Savella
Generic Name
Milnacipran
View Brand Information FDA approval date: April 17, 2009
Classification: Serotonin and Norepinephrine Reuptake Inhibitor
Form: Tablet, Kit
What is Savella (Milnacipran)?
SAVELLA is indicated for the management of fibromyalgia. SAVELLA is not approved for use in pediatric patients [see Use in Specific Populations.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment